Navigation Links
Smith & Nephew Takes Single Injection PMA to Next Stage
Date:8/19/2009

RALEIGH and DURHAM, N.C., Aug. 19 /PRNewswire-FirstCall/ -- Smith & Nephew (NYSE: SNN; LSE: SN) Biologics & Spine is proceeding to the next stage in the approval process for the U.S. launch of DUROLANE(R) Single Injection, Stabilized Hyaluronic Acid.

Representatives from the product developer, Q-Med AB of Sweden ("Q-Med"), and their global commercial partner, Smith & Nephew met today with the FDA's Orthopaedic and Rehabilitation Devices Advisory Committee to discuss clinical evidence for the use of DUROLANE(R) in the treatment of knee pain caused by osteoarthritis ("OA").

The FDA Advisory Committee did not recommend DUROLANE(R) for immediate approval, requesting further information as part of the Premarket Approval ("PMA") process for the product. Smith & Nephew plans to work with Q-Med and the FDA to provide the data required.

Mark Augusti, President of Smith & Nephew Biologics & Spine, said: "We are committed to expanding our range of HA therapies in the United States. Use of our multi-injection SUPARTZ(R) Joint Fluid Therapy as a treatment for knee OA continues to increase and we are exploring its potential for other indications."

Q-Med CEO and founder Bengt Agerup said: "We are continuing the clinical development of DUROLANE(R) in collaboration with Smith & Nephew to provide satisfactory clinical evidence of DUROLANE(R)'s performance. We remain committed to our goal of providing U.S. physicians and patients access to a non-animal single injection product."

Ken Reali, SVP and General Manager of Biologics & Spine, added: "Our meeting with the Advisory Committee on single injection DUROLANE(R) provided some very useful and valuable feedback on our Premarket Approval application. We intend to work with our Q-Med partners and the FDA to initiate the next steps in making this highly successful global product available to U.S. patients."

Smith & Nephew and Q-Med have an exclusive partnership for the global development and commercialization of DUROLANE(R). It is already marketed in 32 countries, including Canada, and has been used to treat the symptoms of OA in more than 350,000 patients worldwide.

For media enquiries please call Katie Cralle, Brunswick Group 917 535 4543.

Editors Notes:

  1. DUROLANE(R) is produced using the unique NASHA(TM) (Stabilized Non-Animal Hyaluronic Acid) technology, a patented process for the production of stabilized hyaluronic acid. DUROLANE(R) is a transparent gel which contains high levels of HA (Hyaluronic Acid). HA is a naturally occurring molecule that provides lubrication and cushioning in a normal joint. DUROLANE is injected into knee joints affected by osteoarthritis to relieve pain, restore lubrication and cushioning.
  2. DUROLANE(R) is currently marketed in some 32 countries, including Canada, Europe, Scandinavia, the Middle East, the Far East and South America. Outside the United States, it is approved for the treatment of osteoarthritis of the hip and knee.
  3. SUPARTZ(R) is a registered trademark of Seikagaku Corp.

About Smith & Nephew - Smith & Nephew is a global medical technology business, specializing in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies. Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2008 were $3.8 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In particular, statements regarding planned growth in our business and in our operating margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors. All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.


'/>"/>
SOURCE Smith & Nephew
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Especially Yours and Paula Young Team up with Diahann Carroll and Jaclyn Smith in the Fight Against Breast Cancer
2. GlaxoSmithKline Responds to JAMA Articles
3. The Will and Jada Smith Family Foundation and Maybelline Join Forces With the Lupus Foundation of America for a Star-studded Gala to Raise Awareness for Lupus
4. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against LCA-Vision Inc.
5. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
6. TIGroup Names Dennis M. Smith as Chief Financial Officer
7. The American Liver Foundation Appoints Rick Smith, a Twenty-Year Veteran of The MS Society, as Chief Executive Officer
8. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
9. Smith & Nephew Endoscopys KINSA(R) RC Suture Anchor Designed for Secure Repair of Rotator Cuff Injuries
10. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
11. Smithfield(R) LEAN GENERATION(R) Announces DELI FOR THE CURE(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology: